Sponsors (3)
The bill strengthens identification, prevention, coordination, and prosecution against pill-form counterfeit fentanyl and meth to reduce accidental overdoses and disrupt supply, but does so at the cost of expanded enforcement and criminal exposure for individuals, higher public expenditures, potential diversion from treatment, and risks of stigmatizing messaging and constrained transparency.
Consumers — especially young people and families — are more protected because the bill clearly defines and targets pill-form counterfeit fentanyl/methamphetamine and mandates prevention and education campaigns, reducing accidental exposure and overdoses.
Law enforcement and prosecutors gain clearer legal grounds, better interagency coordination, and required data reporting to investigate, seize, and prosecute counterfeit fentanyl/methamphetamine more effectively, enabling more targeted interdiction of illicit supply.
Federal oversight and regular, detailed reporting to Congress and agencies will improve policy targeting and allow adjustments to prevention, prosecution, and public-health strategies based on up-to-date data.
Individuals — particularly young adults, low-income people, and other marginalized groups — could face increased arrests, prosecutions, or harsher penalties because broader counterfeit and controlled-substance definitions enable expanded enforcement.
Taxpayers and public budgets may incur significant costs from expanded enforcement, audits, forensic reporting, and DEA activities, and resources may be shifted away from treatment and harm-reduction programs toward policing and prosecution.
Public-awareness campaigns that are broad or not evidence-based risk stigmatizing people who use drugs and failing to reach the highest-risk groups (including people with disabilities and racial/ethnic minorities), reducing overall harm-reduction effectiveness.
Based on analysis of 5 sections of legislative text.
Defines pill-form counterfeit fentanyl/methamphetamine, requires a DEA operational plan and audits of awareness campaigns, and mandates annual DOJ reports on seizures and prosecutions.
Introduced October 30, 2025 by Charles Ernest Grassley · Last progress October 30, 2025
Requires federal drug enforcement and policy offices to treat pill-shaped counterfeit fentanyl or methamphetamine as a distinct enforcement and public-health priority by defining these substances, directing the DEA to produce an operational and response plan within 180 days, auditing existing public-awareness efforts, and requiring an annual DOJ report on seizures, prosecutions, convictions, and prevention activity. The bill adds a statutory definition for "counterfeit fentanyl or methamphetamine substance," instructs review and tailoring of education campaigns (including youth-focused work), and mandates detailed, aggregate reporting on law enforcement and prosecutorial activity related to pill-form counterfeit drugs.